1. Why does circadian timing of administration matter for immune checkpoint inhibitors’ efficacy?
   Abdoulaye Karaboué et al, 2024, British Journal of Cancer CrossRef
2. Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer
   Adrien Rousseau et al, 2023, European Journal of Cancer CrossRef
3. Nivolumab
   , 2023, Reactions Weekly CrossRef
4. A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody
   T. Koyama et al, 2024, ESMO Open CrossRef
5. Management of Kidney Cancer Relapse to Adjuvant Pembrolizumab: Early Insights and Questions for a Newly Emerging Space
   Martin H. Voss et al, 2024, European Urology CrossRef
6. REFINE-Lung implements a novel multi-arm randomised trial design to address possible immunotherapy overtreatment
   Ehsan Ghorani et al, 2023, The Lancet Oncology CrossRef